Hartmannuv Roztok Viaflo Baxter

Hartmannuv Roztok Viaflo Baxter is an intravenous electrolyte solution containing potassium chloride, sodium chloride, calcium chloride dihydrate, and sodium lactate. It is supplied as a sterile solution for infusion, formulated to provide balanced electrolytes and fluid volume. Marketed in the European Union, it is used for fluid and electrolyte replacement in patients with hypovolemia, metabolic acidosis, or postoperative fluid loss under medical supervision and appropriate monitoring.

Hartmannuv Roztok Viaflo Baxter is indicated for clinical situations and that require rapid restoration of extracellular fluid volume and electrolyte balance.

- Fluid replacement in patients with hypovolemia due to blood loss, dehydration, or burns. - Electrolyte replenishment for conditions associated with sodium, potassium, or calcium deficits. - Correction of metabolic acidosis by providing lactate which is metabolized to bicarbonate. - Support during major surgery or postoperative care to maintain intravascular volume. - Use in pediatric or adult patients when balanced electrolyte solutions are required.

The safety profile of Hartmannuv Roztok Viaflo Baxter reflects the typical reactions observed with intravenous electrolyte solutions.

Common: - Mild vein irritation or pain at the infusion site, usually a brief burning sensation that resolves after the line is removed. - Transient nausea or vomiting during or shortly after infusion, typically self‑limiting. - Slight increase in serum sodium or potassium that normalizes after therapy, monitored with routine labs.

Serious: - Hyperkalemia leading to cardiac arrhythmia, which may present as palpitations, dizziness, or serious rhythm disturbances. - Hypernatremia causing neurological symptoms such as confusion, lethargy, or seizures, especially in patients with impaired water balance. - Severe allergic reaction (anaphylaxis) with rash, swelling, bronchospasm, or hypotension.

When prescribing Hartmannuv Roztok Viaflo Baxter, clinicians should consider several precautions to ensure safe administration.

- Assess baseline electrolyte levels and renal function before initiating therapy. - Adjust infusion rate in patients at risk of fluid overload, such as those with heart failure or pulmonary edema. - Monitor serum potassium and sodium frequently during treatment, especially in patients receiving other electrolyte-modifying drugs. - Use caution in neonates, infants, and the elderly due to altered fluid and electrolyte handling. - Avoid rapid infusion that may cause hyperosmolar shifts and vascular irritation. - Discontinue the solution if signs of allergic reaction or severe electrolyte imbalance develop.

Hartmannuv Roztok Viaflo Baxter may interact with other medications that affect fluid balance, electrolytes, or acid‑base status.

Avoid: - Concomitant use with high‑dose potassium supplements or potassium‑sparing diuretics, which can precipitate hyperkalemia. - Simultaneous administration with hypertonic saline solutions, which may cause excessive sodium load.

Use with caution: - Co‑administration with ACE inhibitors or ARBs, requiring close monitoring of potassium and renal function. - Use together with loop diuretics, as they can alter sodium and calcium balance and necessitate electrolyte checks. - Combination with insulin or beta‑agonists, which shift potassium intracellularly and may lead to hypokalemia.